KLTO

Klotho Neurosciences

0.4004 USD
-0.0238
5.61%
At close Updated Dec 12, 4:00 PM EST
Pre-market
After hours
0.4070
+0.0066
1.65%
1 day
-5.61%
5 days
-18.19%
1 month
-22.33%
3 months
-32.16%
6 months
-79.98%
Year to date
-42.76%
1 year
-9.25%
5 years
-95.95%
10 years
-95.95%
 

About: Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Employees: 3

0
Funds holding %
of 7,507 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™